BR9608041A - Oligossacarídeo sulfatado processo para o tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório de um paciente humano ou outro paciente animal de sangue quente uso de um oligossacarídeo e composição farmacêutica ou veterinária para tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório - Google Patents

Oligossacarídeo sulfatado processo para o tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório de um paciente humano ou outro paciente animal de sangue quente uso de um oligossacarídeo e composição farmacêutica ou veterinária para tratamento anti-angiogênico anti-metastático e/ou anti-inflamatório

Info

Publication number
BR9608041A
BR9608041A BR9608041A BR9608041A BR9608041A BR 9608041 A BR9608041 A BR 9608041A BR 9608041 A BR9608041 A BR 9608041A BR 9608041 A BR9608041 A BR 9608041A BR 9608041 A BR9608041 A BR 9608041A
Authority
BR
Brazil
Prior art keywords
metastatic
inflammatory
oligosaccharide
angiogenic treatment
pharmaceutical
Prior art date
Application number
BR9608041A
Other languages
English (en)
Other versions
BR9608041B8 (pt
BR9608041B1 (pt
Inventor
William Butler Cowden
Christopher Richard Parish
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3786969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9608041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Australian filed Critical Univ Australian
Publication of BR9608041A publication Critical patent/BR9608041A/pt
Publication of BR9608041B1 publication Critical patent/BR9608041B1/pt
Publication of BR9608041B8 publication Critical patent/BR9608041B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
BRPI9608041-8B8A 1995-04-28 1996-04-24 Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório. BR9608041B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPN2618A AUPN261895A0 (en) 1995-04-28 1995-04-28 Preparation and use of sulfated oligosaccharides
AUPN2618 1995-04-28
PCT/AU1996/000238 WO1996033726A1 (en) 1995-04-28 1996-04-24 Preparation and use of sulfated oligosaccharides

Publications (3)

Publication Number Publication Date
BR9608041A true BR9608041A (pt) 1999-01-26
BR9608041B1 BR9608041B1 (pt) 2012-02-22
BR9608041B8 BR9608041B8 (pt) 2014-11-18

Family

ID=3786969

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9608041-8B8A BR9608041B8 (pt) 1995-04-28 1996-04-24 Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório.

Country Status (26)

Country Link
US (1) US6143730A (pt)
EP (1) EP0837683B1 (pt)
JP (2) JP4514240B2 (pt)
KR (1) KR100591960B1 (pt)
CN (1) CN1090021C (pt)
AT (1) ATE463250T1 (pt)
AU (1) AUPN261895A0 (pt)
BR (1) BR9608041B8 (pt)
CA (1) CA2218872C (pt)
CZ (1) CZ341097A3 (pt)
DE (1) DE69638158D1 (pt)
EA (1) EA001199B1 (pt)
EE (1) EE9700277A (pt)
ES (1) ES2341924T3 (pt)
FI (1) FI974060A7 (pt)
HU (1) HUP9802394A2 (pt)
IL (1) IL118047A (pt)
IS (1) IS4596A (pt)
NO (1) NO974911L (pt)
NZ (1) NZ305815A (pt)
PL (1) PL184357B1 (pt)
PT (1) PT837683E (pt)
TR (1) TR199701264T1 (pt)
TW (1) TW446710B (pt)
WO (1) WO1996033726A1 (pt)
ZA (1) ZA963339B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO556297A0 (en) * 1997-03-11 1997-04-10 Australian National University, The Sulfated oligosaccharides having anticoagulant/ antithrombotic activity
DK1014996T3 (da) * 1997-08-28 2003-09-29 Univ Washington Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
AUPO888497A0 (en) * 1997-09-01 1997-09-25 Australian National University, The Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
AUPO976897A0 (en) * 1997-10-14 1997-11-06 Australian National University, The Use of sulfated oligosaccharides in lowering blood triglyceride levels
GB9802725D0 (en) * 1998-02-09 1998-04-08 Ciba Geigy Ag Organic compounds
US7081448B2 (en) * 1998-11-24 2006-07-25 Wyeth Benzyllactobionamides as inhibitors of smooth muscle cell proliferation
US7132402B2 (en) * 1998-11-24 2006-11-07 Wyeth Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
GB0001481D0 (en) * 2000-01-21 2000-03-15 Theryte Ltd System for delivering a medicament
US20050137167A1 (en) 2001-09-12 2005-06-23 Benito Casu Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
FR2808687B1 (fr) * 2000-04-27 2003-12-05 Goemar Lab Sa Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose
JP4676048B2 (ja) * 2000-07-10 2011-04-27 生化学工業株式会社 脱髄性疾患処置剤
US7407773B2 (en) * 2000-11-03 2008-08-05 Procognia, Ltd. Method for characterizing a carbohydrate polymer
TW519716B (en) * 2000-12-19 2003-02-01 Tokyo Electron Ltd Wafer bias drive for a plasma source
EP1353556A4 (en) * 2001-01-23 2009-09-09 Massachusetts Inst Technology SYNTHESIS OF HEPARIN AND OTHER GLYCOSAMINOGLYCANS IN SOLID PHASE AND SOLUTION PHASE
CN1394867A (zh) * 2001-07-06 2003-02-05 中国科学院生态环境研究中心 可作药物的寡糖和其制备方法及含该寡糖的药物组合物
KR20030046810A (ko) * 2001-12-06 2003-06-18 은삼제약 주식회사 콘드로이친 황산의 분해산물을 포함하는 관절염 예방 또는치료용 약학적 조성물
AUPS052802A0 (en) * 2002-02-15 2002-03-07 Praxis Pharmaceuticals International Pty Ltd Carbohydrate-based anti-wrinkle and tissue remodelling compounds
US7575886B2 (en) 2002-03-11 2009-08-18 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
WO2005054493A2 (en) * 2003-06-12 2005-06-16 Mayo Foundation For Medical Education And Research Altered activity of toll-like receptors
KR101156273B1 (ko) * 2004-03-04 2012-06-13 프로젠 파마슈티칼즈 리미티드 황산화 올리고사카라이드 유도체
JP5404406B2 (ja) * 2006-10-20 2014-01-29 ジ オーストラリアン ナショナル ユニバーシティ 細胞外マトリクスの分解の阻害
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
NZ599928A (en) * 2007-05-31 2012-08-31 Glycan Biosciences Use of pentosan polysulfate for treatment or prophylaxis of asthma
FR2917971B1 (fr) 2007-06-28 2009-10-23 Engelhard Lyon Soc Par Actions Composition amincissante
WO2009000935A1 (en) * 2007-06-28 2008-12-31 Basf Beauty Care Solutions France Sas Slimming composition
US8153611B2 (en) * 2007-06-28 2012-04-10 Basf Beauty Care Solutions France S.A.S. Use of sulfated oligosaccharides as slimming cosmetic ingredients
ES2584927T7 (es) 2007-10-16 2020-11-05 Progen Pg500 Series Pty Ltd Derivados de oligosacáridos sulfatados novedosos
WO2009078015A2 (en) * 2007-12-18 2009-06-25 Procognia (Israel) Ltd Method and assay for glycosylation pattern detection related to cell state of stem cells
CN102046781A (zh) * 2008-05-30 2011-05-04 动量制药公司 糖结构以及制造和使用此类结构的方法
EP2149580A1 (en) 2008-07-15 2010-02-03 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Mimetics of sulfated oligosaccharides
US9029530B2 (en) 2009-01-02 2015-05-12 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US8592140B2 (en) 2009-01-02 2013-11-26 Biomarin Pharmaceutical Inc. Detection of oligosaccharides
US8232073B2 (en) 2009-01-02 2012-07-31 Zacharon Pharmaceuticals, Inc. Quantification of non-reducing end glycan residual compounds
US8809009B2 (en) 2009-01-02 2014-08-19 Biomarin Pharmaceutical Inc. Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
GB0915315D0 (en) 2009-09-03 2009-10-07 Univ Manchester Use of non-digestible oligosaccharides
JP5701498B2 (ja) * 2009-12-01 2015-04-15 公益財団法人微生物化学研究会 炎症性細胞からのヘパラナーゼの放出抑制剤、抗炎症剤、及び薬用組成物
CN102791742B (zh) * 2010-01-19 2014-12-24 动量制药公司 评价肝素制剂
JPWO2011122321A1 (ja) * 2010-03-29 2013-07-08 国立大学法人名古屋大学 ヘパリン結合性蛋白に対する生理活性阻害剤
DK2646037T3 (en) * 2010-12-01 2019-03-04 Univ Australian National use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
CA2827383A1 (en) * 2011-02-18 2012-08-23 President And Fellows Of Harvard College Molecular switch for neuronal outgrowth
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN102199175A (zh) * 2011-04-07 2011-09-28 福州大学 硫酸类肝素二糖的制备纯化方法及其纯化产品
JP2014516058A (ja) * 2011-06-09 2014-07-07 基亜生物科技股▲ふん▼有限公司 肝癌の再発、悪化または転移の抑制に用いる医薬組成物
ES2699238T3 (es) * 2012-01-30 2019-02-08 Baxalta GmbH Polisacáridos sulfatados o sulfonatados no anticoagulantes
SG11201509430WA (en) * 2013-05-16 2015-12-30 Agency Science Tech & Res Heparan sulphates
CA2946679A1 (en) 2014-05-08 2015-11-12 Immunexcite, Inc. Immunomodulating .beta.-1,6-d-glucans
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
CZ306662B6 (cs) * 2015-06-26 2017-04-26 Contipro A.S. Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
JP2016199579A (ja) * 2016-07-08 2016-12-01 基亜生物科技股▲ふん▼有限公司Ｍｅｄｉｇｅｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． 肝癌の再発、悪化または転移の抑制に用いる医薬組成物
MX2019006863A (es) 2016-12-13 2019-09-13 Beta Therapeutics Pty Ltd Inhibidores de heparanasa y uso de los mismos.
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
US11141428B2 (en) * 2017-12-12 2021-10-12 Academia Sinica Octasaccharides and uses thereof
WO2019113646A1 (en) * 2017-12-15 2019-06-20 Griffith University Sulfation method
JP6619830B2 (ja) * 2018-02-22 2019-12-11 基亜生物科技股▲ふん▼有限公司Ｍｅｄｉｇｅｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐ． 肝癌の再発、悪化または転移の抑制に用いる医薬組成物
NL2024493B1 (en) * 2019-12-16 2021-09-02 Logick Energetics B V Pharmaceutical composition for preventing or stopping metastases
EP4076439A1 (en) 2019-12-18 2022-10-26 Logick Energetics Pharmaceutical composition for use in preventing or stopping metastases
CN110917208B (zh) * 2019-12-27 2021-02-12 浙江医院 硫酸化甘露葡萄糖醛酸六糖在防治动脉粥样硬化中的应用
CN111904968A (zh) * 2020-08-21 2020-11-10 青岛市中心医院 硫酸半乳四糖及其衍生物在制备抗上皮细胞黏附药物中的应用
CN113633658A (zh) * 2021-07-09 2021-11-12 南京理工大学 硫酸葡半乳寡聚糖在制备抗凝血和/或抗血栓药物中的应用
CN114134188B (zh) * 2021-07-23 2023-03-17 光明乳业股份有限公司 一种发酵小麦麸皮合成胞外多糖的方法
CN116650425B (zh) * 2023-07-13 2025-06-27 晟迪生物医药(苏州)有限公司 糖酯化合物或其盐在冷冻保护、冷冻干燥保护中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869530B (en) * 1985-12-24 1987-10-28 Marion Laboratories Inc Use of synthetic sulfated saccharides to enhance wound healing
FR2597484B1 (fr) * 1986-04-17 1988-12-23 Sanofi Sa Glycosaminoglycanes de type heparine ou heparane-sulfate dotes d'une activite sur la division et la differentiation cellulaires, leur preparation et leurs applications therapeutiques.
US5541166A (en) * 1987-01-23 1996-07-30 The Australian National University Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity
EP0338092A1 (en) * 1987-10-30 1989-10-25 Chugai Seiyaku Kabushiki Kaisha Anti-hiv agent
US5506210A (en) * 1988-08-19 1996-04-09 The Australian National University Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
JPH0296588A (ja) * 1988-09-29 1990-04-09 Rikagaku Kenkyusho 硫酸化オリゴ糖及びその関連物質
JP2956090B2 (ja) * 1989-10-30 1999-10-04 大日本インキ化学工業株式会社 オリゴ糖誘導体
JPH0578382A (ja) * 1990-08-23 1993-03-30 Dainippon Ink & Chem Inc 硫酸化アルキルオリゴ糖またはその生理学的に許容される塩およびこれを有効成分とする抗ウイルス剤
CA2061370A1 (en) * 1991-03-13 1992-09-14 Markus Hosang Pharmaceutical preparations
CA2108569A1 (en) * 1991-04-17 1992-10-18 H. Edward Conrad Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
JPH06256373A (ja) * 1993-01-11 1994-09-13 Dainippon Ink & Chem Inc 硫酸化オリゴ糖配糖体アシル化物およびこれを有効成分とする抗ウイルス剤
US5459257A (en) * 1993-01-11 1995-10-17 Dainippon Ink And Chemicals, Inc. Sulfated oligoglycoside acylate and antiviral agent containing the same as active ingredient
FR2710741B1 (fr) * 1993-09-30 1995-10-27 Commissariat Energie Atomique Capteur électronique destiné à la caractérisation de grandeurs physiques et procédé de réalisation d'un tel capteur.
US5739115A (en) * 1993-10-07 1998-04-14 Glycomed Incorporated Sulfated maltooligosaccharides with heparin-like properties
CA2171465A1 (en) * 1993-10-07 1995-04-13 Peter Fugedi Highly sulfated maltooligosaccharides with heparin-like properties

Also Published As

Publication number Publication date
IS4596A (is) 1997-10-21
JP4514240B2 (ja) 2010-07-28
PT837683E (pt) 2010-07-09
JP2009235085A (ja) 2009-10-15
EP0837683A1 (en) 1998-04-29
KR100591960B1 (ko) 2007-12-04
CN1090021C (zh) 2002-09-04
BR9608041B8 (pt) 2014-11-18
NO974911L (no) 1997-12-29
ES2341924T3 (es) 2010-06-29
NO974911D0 (no) 1997-10-24
ZA963339B (en) 1997-01-03
MX9708289A (es) 1998-06-30
FI974060A0 (fi) 1997-10-27
EP0837683B1 (en) 2010-04-07
WO1996033726A1 (en) 1996-10-31
AUPN261895A0 (en) 1995-05-18
HUP9802394A2 (hu) 1999-02-01
CZ341097A3 (cs) 1998-03-18
FI974060L (fi) 1997-10-27
IL118047A0 (en) 1996-08-04
EA001199B1 (ru) 2000-12-25
TR199701264T1 (xx) 1998-02-21
PL323080A1 (en) 1998-03-02
KR19990008198A (ko) 1999-01-25
NZ305815A (en) 1999-05-28
ATE463250T1 (de) 2010-04-15
TW446710B (en) 2001-07-21
CA2218872A1 (en) 1996-10-31
JPH11504018A (ja) 1999-04-06
CN1183043A (zh) 1998-05-27
PL184357B1 (pl) 2002-10-31
EE9700277A (et) 1998-04-15
EA199700347A1 (ru) 1998-06-25
BR9608041B1 (pt) 2012-02-22
US6143730A (en) 2000-11-07
CA2218872C (en) 2007-02-20
IL118047A (en) 2000-11-21
DE69638158D1 (de) 2010-05-20
EP0837683A4 (en) 2007-07-04
FI974060A7 (fi) 1997-10-27

Similar Documents

Publication Publication Date Title
BR9608041B8 (pt) Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório.
BR0001468A (pt) ácidos dioxiciclopentil hidroxânicos
DE60323756D1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
ATE534656T1 (de) Neue oligosaccharide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69425671D1 (de) Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
BRPI0408236A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
ES2124424T3 (es) Azadioxacicloalquenos substituidos y su empleo como fungicidas.
BR0312957A (pt) Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
BR9710737A (pt) Pentafluorobenzenosulfonamidas e análogos.
BR9808366A (pt) Derivados de ácido hidroxâmico substituìdo com aril ou heteroaril sulfonamidas; processo para sua preparação e seu uso como produtos farmacêuticos
CA2261597A1 (fr) Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9915480A (pt) Azalìdeos de 13 membros e a sua utilização como agentes antibióticos
BR0012610A (pt) Novo derivado de difenilpiperidina
ES2098947T3 (es) Derivados de beta,beta-dimetil-4-piperidinoetanamina como inhibidores de la biosintesis del colesterol.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
NO950243L (no) Nye nimesulidsalt-cyklodekstrin-inklusjonskomplekser
BR9808008A (pt) Processo para o tratamento anticoagulante e/ou antitrombótico de um ser humano ou outro paciente animal de sangue quente, usos de um oligossacarìdeo sulfatado e na fabricação de um medicamento, e, composição farmacêutica ou veterinária para tratamento anticoagulante e/ou antitrombótico.
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
BR9811422A (pt) Processo para a inibição de hiperplasia celular de músculo liso vascular em um paciente humano ou em outro paciente animal de sangue quente necessitando de tal tratamento, uso de pelo menos um oligossacarìdeo sulfatado, e, composição farmacêutica ou veterinária para a inibição de hiperplasia celular de músculo liso vascular
DE60003074D1 (de) Fusidinsäure-derivate
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
DE69323191D1 (de) Wasserlösliche retinoide
BR0010338A (pt) Composto enanciomericamente enriquecido, composição farmacêutica, método para tratar uma doença ou condição mediada por cck-a, uso de um composto, e, processo para a preparação de um composto

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO DO PRESENTE PEDIDO, UMA VEZ QUE: O QUADRO PROPOSTO NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM O ART. 13 DA LPI), AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI), E OS OLIGOSSACARIDEOS SULFATADOS SINTETICOS COM CORRESPONDENTES NATURAIS NAO SAO CONSIDERADOS INVENCAO DE ACORDO COM O ART. 10 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/02/2012, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061557/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132378-91.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: RECKITT BENCKISER HEALTHCARE (UK) LIMITED, SANOFI-AVERTIS, SEPSICURE, L.L.C, THE AUSTRALIAN NATIONAL UNIVERSITY, THE PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY UNDIVIDED TRINITY OF QUEEN ELIZA

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2146 DE 22/02/2012, QUANTO AO PRAZO DE VALIDADE CONFORME DECISAO DA 13A VARA FEDERAL DO RIO DE JANEIRO.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061557/13 SECAO JUDICIARIA DO RIO DE JANEIRO - 13A VARA FEDERAL PROCESSO NO 2013.51.01.132378-8 AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU(S): RECKITT BENCKISER HEALTHCARE (UK) LIMITED, SANOFI-AVENTIS, SEPSICURE, L.L.C. E THE AUSTRALIAN NATIONAL UNIVERSITY DECISAO: ANTECIPO OS EFEITOS DA TUTELA, A FIM DE DETERMINAR A IMEDIATA READEQUACAO DO PRAZO DE VIGENCIA DAS PATENTES PI9607679-8, PI9707943-0, PI9508584-0 E PI9608041-8 PARA VINTE ANOS CONTADOS A PARTIR DOS RESPECTIVOS DEPOSITOS, NOS TERMOS DO PARAGRAFO UNICO DO ART. 229 C/C O CAPUT DO ART. 40 DA LPI, CONFORME TABELA A SEGUIR: TITULAR: RECKITT BENCKISER HEALTHCARE (UK) LIMITED - PI9607679-8 - PRAZO DE VIGEN

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/04/2016

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/702 (2006.01), A61K 31/722 (2006.0